MX2018007105A - Toxina botulinica para trastornos primarios del estado de animo y afectivo que usan neurotransmisor. - Google Patents

Toxina botulinica para trastornos primarios del estado de animo y afectivo que usan neurotransmisor.

Info

Publication number
MX2018007105A
MX2018007105A MX2018007105A MX2018007105A MX2018007105A MX 2018007105 A MX2018007105 A MX 2018007105A MX 2018007105 A MX2018007105 A MX 2018007105A MX 2018007105 A MX2018007105 A MX 2018007105A MX 2018007105 A MX2018007105 A MX 2018007105A
Authority
MX
Mexico
Prior art keywords
mood
affect
neurotransmitter
disorders
botulinum toxin
Prior art date
Application number
MX2018007105A
Other languages
English (en)
Inventor
Borodic Gary
Acquadro Martin
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/966,759 external-priority patent/US20160095908A1/en
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of MX2018007105A publication Critical patent/MX2018007105A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Abstract

La invención provee métodos para el tratamiento de trastornos primarios del estado de ánimo y afectivo, que incluyen trastornos depresivos, ansiedad, trastornos del sueño y trastornos del SNC, que comprenden la administración de una neurotoxina.
MX2018007105A 2015-12-11 2016-12-09 Toxina botulinica para trastornos primarios del estado de animo y afectivo que usan neurotransmisor. MX2018007105A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/966,759 US20160095908A1 (en) 2005-06-14 2015-12-11 Botulinum Toxin for Primary Disorders of Mood and Affect using Neurotransmitter CNS imaging Studies
PCT/US2016/065898 WO2017100624A1 (en) 2015-12-11 2016-12-09 Botulinum toxin for primary disorders of mood and affect using neurotransmitter

Publications (1)

Publication Number Publication Date
MX2018007105A true MX2018007105A (es) 2018-09-07

Family

ID=59013649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007105A MX2018007105A (es) 2015-12-11 2016-12-09 Toxina botulinica para trastornos primarios del estado de animo y afectivo que usan neurotransmisor.

Country Status (13)

Country Link
EP (1) EP3386538A4 (es)
JP (1) JP2019504824A (es)
KR (1) KR20180093983A (es)
CN (1) CN109069609A (es)
AU (1) AU2016366428A1 (es)
BR (1) BR112018011663A2 (es)
CA (1) CA3007816A1 (es)
CO (1) CO2018007096A2 (es)
IL (1) IL259825A (es)
MX (1) MX2018007105A (es)
RU (1) RU2018125034A (es)
SG (1) SG11201804840SA (es)
WO (1) WO2017100624A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021137667A1 (ko) * 2019-12-30 2021-07-08 주식회사 에이티지씨 보툴리눔 신경독소를 포함하는 파킨슨병 치료용 조성물 및 이를 이용한 파킨슨병 치료 방법
CN114384185A (zh) * 2022-01-20 2022-04-22 北京航空航天大学 用于检测γ-氨基丁酸含量的试剂在制备诊断静脉流出障碍性疾病的试剂盒中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609112B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
WO2005072433A2 (en) * 2004-01-26 2005-08-11 The Board Of Trustees Of The Leland Stanford Junior University Toxin induced sympathectomy
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
CA2661220A1 (en) * 2006-08-21 2008-02-28 James R. Hauske Multimediator transporter inhibitors for use in treatment of central nervous system disorders
WO2010013495A1 (ja) * 2008-07-31 2010-02-04 財団法人化学及血清療法研究所 高度精製ボツリヌス毒素治療剤を有効成分として含有する薬学的組成物およびその利用
US9393291B2 (en) * 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations

Also Published As

Publication number Publication date
IL259825A (en) 2018-07-31
KR20180093983A (ko) 2018-08-22
RU2018125034A (ru) 2020-01-13
EP3386538A4 (en) 2019-07-17
JP2019504824A (ja) 2019-02-21
EP3386538A1 (en) 2018-10-17
WO2017100624A1 (en) 2017-06-15
RU2018125034A3 (es) 2020-04-15
CO2018007096A2 (es) 2018-11-22
CN109069609A (zh) 2018-12-21
AU2016366428A1 (en) 2018-06-28
BR112018011663A2 (pt) 2018-12-04
SG11201804840SA (en) 2018-07-30
CA3007816A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
MX2020010262A (es) Manufactura de neurotoxinas de clostridium botulinum recombinantes.
MX2020007166A (es) Composiciones para modular la expresion de sod-1.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MX2023000563A (es) Metodos y procesos para evaluacion no invasiva de variaciones geneticas.
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
BR112017007472A2 (pt) 2-amino-3-fluoro-3-(fluoro metil)-6-metil-6-fenil- 3,4,5,6-tetra-hidropiridinas como inibidores de bace1
HK1257762A1 (zh) 純化梭菌神經毒素的方法
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2019002672A (es) Usos de antagonistas de il-13 para el tratamiento de dermatitis atopica.
MX2018003536A (es) Metodos para el tratamiento de la epilepsia.
DK3282008T3 (da) Sporulationsfremgangsmåde for Bacillus bacterium
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
CL2018000009A1 (es) Un proceso para tratar leche
PH12017501864A1 (en) Compositions and methods for treating autism
PH12017500602A1 (en) Methods for treating ocular conditions
MX2016009537A (es) Metodo para tratar ropa.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
MX2021006439A (es) Reguladores del cftr y metodos para su uso.
PH12017501549B1 (en) Peptides for inhibiting angiogenesis
MX2018007105A (es) Toxina botulinica para trastornos primarios del estado de animo y afectivo que usan neurotransmisor.
SG11202002876WA (en) Treatment of autonomic disorders with botulinum toxin
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
MX2018000694A (es) Tratamiento del prurito.